TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17413684

Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg twice a day
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Etravirine 800 mg twice a day
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (optimized regimens of at least three antiretroviral agents)
Number of subjects: 199
Study: 15752409

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 microg added to 18 mg hyperbaric ropivacaine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline group (3 ml of 18 mg hyperbaric ropivacaine + 0.5 ml saline)
Number of subjects: 31
Study: 12139647

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nurse presence
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 11307032

Group type: EXPERIMENTAL
Intervention: Step-down therapy with 1200 microg/day of BDP for 4 weeks with short-term oral steroid (prednisolone, 0.5 mg/day for 1 week)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Step-down therapy with 1200 microg/day of BDP for 4 weeks without oral steroids
Number of subjects: 82

Group type: COMPARATOR
Intervention: Step-up therapy with 400 microg/day of BDP for 4 weeks, then 800 microg/day for another 4 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Step-down therapy with 1200 microg/day of BDP for 4 weeks with short-term oral steroid
Number of subjects: 82
Study: 9817114

Group type: EXPERIMENTAL
Intervention: Telephone mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mail mode
Number of subjects: 0
Study: 8001304

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 3056555

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate mouthrinse
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 51
Study: 4099843

Group type: EXPERIMENTAL
Intervention: Preseasonal immunization with large doses of ragweed pollen extract
Number of subjects: 21
Study: 760587

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (solvent only)
Number of subjects: 109
Study: 31119479

Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571) at a fixed dose of 600 mg/D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571) in patients with 1p/19q‐codeleted tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec; STI571) at 600 mg/D
Number of subjects: 0
Study: 30368335

Group type: EXPERIMENTAL
Intervention: Eyes closed group (participants closed their eyes for 20 min before the test)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Eyes closed group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Eyes open group (control)
Number of subjects: 45
Study: 27358437

Group type: EXPERIMENTAL
Intervention: Video decision support tool and advance care planning checklist
Number of subjects: 246

Group type: COMPARATOR
Intervention: Verbal description only (Control)
Number of subjects: 246
Study: 24288395

Group type: EXPERIMENTAL
Intervention: Combination treatment with 16 mg azelnidipine (O/A group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Combination treatment with 1 mg indapamide (O/D group)
Number of subjects: 48
Study: 22291207

Group type: EXPERIMENTAL
Intervention: Carboplatin‐pegylated liposomal doxorubicin (CD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin‐paclitaxel (CP)
Number of subjects: 0
Study: 20085177

Group type: EXPERIMENTAL
Intervention: Keishinieppiittokaryojutsubu (KER; decoction) in combination with oral methotrexate (MTX)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Keishinieppiittokaryojutsubu (KER; decoction)
Number of subjects: 13
Study: 17978993

Group type: EXPERIMENTAL
Intervention: 15-min brisk walk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Passive condition
Number of subjects: 60
Study: 15289996

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 78
Study: 12031754

Group type: EXPERIMENTAL
Intervention: Midazolam 20 microg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam 40 microg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 11341634

Group type: EXPERIMENTAL
Intervention: Bilateral lung volume reduction surgery (BLVRS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 28
Study: 7733128

Group type: EXPERIMENTAL
Intervention: i.v. thiamine 200 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 30
Study: 1645492

Group type: EXPERIMENTAL
Intervention: Pipecuronium 70 micrograms.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium 90 micrograms.kg‐1
Number of subjects: 0
Study: 6798734

Group type: EXPERIMENTAL
Intervention: Tocainide (oral analogue of lidocaine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no tocainide)
Number of subjects: 30
Study: 30529901

Group type: EXPERIMENTAL
Intervention: So-Pa (sorafenib followed by pazopanib)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Pa-So (pazopanib followed by sorafenib)
Number of subjects: 377
Study: 29131820

Group type: EXPERIMENTAL
Intervention: Single praziquantel treatment
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Two praziquantel treatments
Number of subjects: 446
Study: 25708494

Group type: EXPERIMENTAL
Intervention: Peritoneal cavity saline irrigation
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 430
Study: 25835230

Group type: EXPERIMENTAL
Intervention: Chito group (3 g/day chitosan)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chito-vita group (3 g/day chitosan plus 2 g/day L-ascorbic acid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (placebo, vehicle only)
Number of subjects: 80
Study: 22067628

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 mg intravenous bolus injection followed by continuous infusion at a rate of 0.1 mg/h for 12 hrs; n = 229)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo (n = 228)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 457
Study: 19418868

Group type: COMPARATOR
Intervention: Straumann-conventional (Sc)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Straumann-Cresco (SCr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Brånemark-conventional (Bc)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Brånemark-Cresco (BCr)
Number of subjects: 20
Study: 17217318

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2mg and norethisterone acetate 1mg (Cliane) daily for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablet daily for 6 months
Number of subjects: 40
Study: 16025025

Group type: EXPERIMENTAL
Intervention: TDR with the CHARITE artificial disc
Number of subjects: 304

Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion with BAK cages and iliac crest bone graft
Number of subjects: 304
Study: 12355489

Group type: EXPERIMENTAL
Intervention: Raynaud's Condition Score (RCS) for RP activity (possible range 0-10)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: AIMS2 mood and tension subscales
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Visual Analog Scales (VAS) for SSc/RP-related measures
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Daily diaries documenting frequency and duration of RP attacks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Global assessment scales by physicians
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Sensitivity to change of RP measures
Number of subjects: 281
Study: 10206791

Group type: EXPERIMENTAL
Intervention: Td-eIPV (single dose)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Td-eIPV (two doses)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Td-eIPV (safety data)
Number of subjects: 368
Study: 8547401

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2203699

Group type: EXPERIMENTAL
Intervention: Large data sets for outcome assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data base evaluations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data base analyses
Number of subjects: 0
Study: 649013

Group type: EXPERIMENTAL
Intervention: Dolo Mobilat film tablets
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30112716

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 45
Study: 27632854

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training sessions with a frequency of 30 Hz and an amplitude of 3 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) training sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham protocol (turned-off vibration plate)
Number of subjects: 20
Study: 24657352

Group type: EXPERIMENTAL
Intervention: Sub-maximal force control in young adults
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sub-maximal force control in older adults
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: White matter structural integrity measures (fractional anisotropy and radial diffusivity)
Number of subjects: 32
Study: 23020939

Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen axetil (50 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular tramadol (100 mg)
Number of subjects: 200
Study: 19789197

Group type: EXPERIMENTAL
Intervention: Baseline 3MS score
Number of subjects: 1793

Group type: EXPERIMENTAL
Intervention: Changes in 3MS and PPM
Number of subjects: 1793

Group type: COMPARATOR
Intervention: Baseline PPMs
Number of subjects: 1793
Study: 17631131

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 3

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 3

Group type: COMPARATOR
Intervention: ibuprofen 800 mg 3 times daily
Number of subjects: 3
Study: 16202199

Group type: EXPERIMENTAL
Intervention: Direct composite resin (Z100, 3M ESPE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Indirect ceramic inlay (IPS Empress, Ivoclar‐Vivadent)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intact teeth
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unrestored teeth (MOD cavity preparation)
Number of subjects: 40
Study: 11856097

Group type: EXPERIMENTAL
Intervention: Prototype slim flexible cystoscope
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard flexible cystoscope
Number of subjects: 200
Study: 10442212

Group type: EXPERIMENTAL
Intervention: Processed coffee samples (Darboven improvement procedure)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-processed coffee samples
Number of subjects: 18
Study: 7496880

Group type: COMPARATOR
Intervention: Information or utilization management intervention (e.g., patients or physician education, telephone follow‐up, patient or physician reminders, home care services)
Number of subjects: 600
Study: 2186324

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (MP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex)
Number of subjects: 136
Study: 378350

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI), 100 rads in 10 fractions over 12 days plus combination chemotherapy (CVP or C-MOPP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Combination chemotherapy (CVP or C-MOPP) alone
Number of subjects: 39
Study: 30444673

Group type: EXPERIMENTAL
Intervention: DTaP‐HBV‐IPV/Hib
Number of subjects: 585

Group type: COMPARATOR
Intervention: DTaP‐HBV‐IPV+ HibA
Number of subjects: 585

Group type: COMPARATOR
Intervention: DTaP‐IPV/Hib+ HBV
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 585
Study: 28287044

Group type: EXPERIMENTAL
Intervention: Teriparatide (Forsteo, 20 μg daily for 2 months postoperatively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 50
Study: 25763518

Group type: EXPERIMENTAL
Intervention: Movement-guided fitness (MOV)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Conventional fitness (FIT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 52
Study: 24341511

Group type: EXPERIMENTAL
Intervention: Feedback plus worksheet
Number of subjects: 4055

Group type: COMPARATOR
Intervention: Feedback alone
Number of subjects: 4055

Group type: COMPARATOR
Intervention: Feedback plus worksheet and feedback alone
Number of subjects: 4055
Study: 21756808

Group type: EXPERIMENTAL
Intervention: Imatinib plus Hyper-CVAD chemotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no allogeneic hematopoietic stem cell transplantation)
Number of subjects: 18
Study: 19339534

Group type: EXPERIMENTAL
Intervention: Alert (Jeneric/Pentron)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SureFil (Dentsply/Caulk)
Number of subjects: 33
Study: 16423143

Group type: EXPERIMENTAL
Intervention: Early psychological intervention using a psychological debriefing format
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no early psychological intervention)
Number of subjects: 158
Study: 12938838

Group type: EXPERIMENTAL
Intervention: Superelastic wire with a force plateau of 0.8‐1 N, activated initially by 4.5 mm and not reactivated during 12 weeks.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Stainless steel wire with a buccal offset of 1 mm, reactivated every four weeks.
Number of subjects: 27
Study: 10950448

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (alpha-tocopherol 1200 IU x day(-1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9018408

Group type: EXPERIMENTAL
Intervention: Testosterone propionate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10184318

Group type: EXPERIMENTAL
Intervention: Levodropropizine (LD) 60 mg t.i.d. as oral drops for 8 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2900919

Group type: EXPERIMENTAL
Intervention: rt-PA 100 mg plus heparin
Number of subjects: 2516

Group type: COMPARATOR
Intervention: Placebo plus heparin
Number of subjects: 2516
Study: 29490105

Group type: EXPERIMENTAL
Intervention: Daily Breakfast Consumption (DBC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intermittent Breakfast Consumption (IBC)
Number of subjects: 27
Study: 25710923

Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer Diabetes (guided self-help intervention, n = 130)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Brief online unguided psychoeducation program for depression (control group, n = 130)
Number of subjects: 260
Study: 22084404

Group type: EXPERIMENTAL
Intervention: MBSR(BC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 82
Study: 20133925

Group type: EXPERIMENTAL
Intervention: Oxygen-conserving devices at 2 L O(2)/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oxygen-conserving devices during exertion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Two systems providing less oxygen than predicted
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Continuous setting of oxygen pulse volume
Number of subjects: 13
Study: 18991094

Group type: EXPERIMENTAL
Intervention: TT homozygotes
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Early septic patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: LPS stimulation (in vitro)
Number of subjects: 44
Study: 16466167

Group type: EXPERIMENTAL
Intervention: Bushen Granule (BSG) combined with Marine Injection (MI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lamivudine (control)
Number of subjects: 90
Study: 12502940

Group type: EXPERIMENTAL
Intervention: Collagen plugs
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Silicone plugs
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moisturizing agent usage
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Corneal/conjunctival fluorescein staining
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ocular comfort
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Visual performance
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 61
Study: 10647800

Group type: EXPERIMENTAL
Intervention: Intravenous methylnaltrexone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 8758162

Group type: EXPERIMENTAL
Intervention: Deflation tool
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual deflation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Free deflation
Number of subjects: 10
Study: 1958439

Group type: EXPERIMENTAL
Intervention: Betahistine 72 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7150932

Group type: EXPERIMENTAL
Intervention: Cefamandole with premedication
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transrectal biopsy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transperineal biopsy
Number of subjects: 45
Study: 30931720

Group type: EXPERIMENTAL
Intervention: CSM referral letter + Dental Information Guide (DIG)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: CSM referral letter alone
Number of subjects: 597

Group type: COMPARATOR
Intervention: Standard letter
Number of subjects: 597
Study: 28735928

Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Almorexant 100 mg
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg (active reference)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 25720711

Group type: COMPARATOR
Intervention: Conventional therapy and rehabilitation training
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Conventional therapy, rehabilitation training and botulinum toxin type A injection
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: AFO plus conventional therapy and rehabilitation training
Number of subjects: 103
Study: 23725204

Group type: EXPERIMENTAL
Intervention: Telaprevir (T) with 24 weeks peginterferon alpha-2a/ribavirin (PR) (T12PR24)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Telaprevir (T) with 48 weeks peginterferon alpha-2a/ribavirin (PR) (T12PR48)
Number of subjects: 722

Group type: COMPARATOR
Intervention: 48 weeks of peginterferon alpha-2a/ribavirin (PR)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR) at week 72
Number of subjects: 722
Study: 22081618

Group type: EXPERIMENTAL
Intervention: Mate tea consumption (330 mL, 3 times a day for 60 days)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Mate tea consumption combined with nutritional counseling
Number of subjects: 58
Study: 19843808

Group type: EXPERIMENTAL
Intervention: Naloxone group (34 mL lidocaine 1.5% with 100 ng naloxone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Naloxone + Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl and 100 ng naloxone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (34 mL lidocaine 1.5% with isotonic saline)
Number of subjects: 112
Study: 17372325

Group type: COMPARATOR
Intervention: Non-dieting program
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dieting condition (meal replacement diet and balanced deficit diet combined)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both dieting and non-dieting groups
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Improvement in self-esteem
Number of subjects: 123
Study: 15201430

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 11517140

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously at the end of surgery and 8 mg in PCA morphine solution
Number of subjects: 81

Group type: COMPARATOR
Intervention: Morphine via PCA syringe
Number of subjects: 81
Study: 9663812

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8083709

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion (2 U or less)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion (adjusted for T and N stage)
Number of subjects: 120
Study: 2973300

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with rt-PA immediately followed by transluminal coronary angioplasty (group 1, n = 183)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Thrombolysis alone (group 2, n = 184)
Number of subjects: 367
Study: 31652195

Group type: EXPERIMENTAL
Intervention: Personalized music intervention (favorite music for 60 minutes, three times a day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Personalized music intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (routine care without music)
Number of subjects: 50
Study: 28647541

Group type: EXPERIMENTAL
Intervention: Response tailored duration of dual sofosbuvir/daclatasvir treatment (8 or 12 weeks based on vRVR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fixed 12 weeks duration of dual sofosbuvir/daclatasvir treatment
Number of subjects: 120
Study: 25280085

Group type: EXPERIMENTAL
Intervention: Fostamatinib (R788) 100 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fostamatinib (R788)
Number of subjects: 0
Study: 23459567

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg or 24 mg)
Number of subjects: 334

Group type: COMPARATOR
Intervention: IFNB-1a
Number of subjects: 334